Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.846,55 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
JE00BYSS4X48
Filter zurücksetzen
© BusinessWire
26.11.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer,...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Reports Third Quarter 2025 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Q3 was a solid quarter with stea...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
15.10.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 202...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
01.10.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Report Third Quarter 2025 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three- and nine-month periods that ended September 30, 2025. T...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
Article
News Preview
Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented today at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 – October 1 in San Francisco and simu...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. “With the Mi...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Upcoming Investor Events
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. “Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few t...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
Article
News Preview
Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitan...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Reports Second Quarter 2025 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “With the first half of 2025 complete...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.06.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Report Second Quarter 2025 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company’s financial results for the three- and six-month periods that ended June 30, 2025. To access th...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Article
News Preview
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. “The data presented today fro...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Upcoming Investor Events
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreati...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Reports First Quarter 2025 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This is a period of meaningful momentum fo...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields th...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen. “Optune Lua is an innovative and urgent...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Report First Quarter 2025 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company’s financial results for the three-month quarter that ended March 31, 2025. To access the conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this present...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Article
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Entering 2024, our team was fo...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
Article
News Preview
Novocure (NASDAQ: NVCR) announced today the official opening of its new global headquarters in the Canton of Zug, Switzerland. Novocure is an oncology company working to extend survival in some of the most aggressive forms of cancer, through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). The co...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Article
News Preview
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFiel...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be j...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line tr...
Themefolio
Profiler
Peergroup
© BusinessWire
27.11.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in Upcoming Investor Conferences
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables, Florida. William Doyle, Executive Chairman, will take part in a fireside chat at 2:10 p.m. ET. Piper Sandler Healthcare Conference on Thursday, Dec...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow e...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable, portable device that produces alternating electric fields known as Tum...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Appoints Christoph Brackmann as Chief Financial Officer
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure fr...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Reports Third Quarter 2024 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a period of strong execution...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to ex...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Report Third Quarter 2024 Financial Results
Article
News Preview
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three-month quarter and first nine months of the year t...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
Article
News Preview
Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Planned CEO Transition
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company’s next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
Article
News Preview
Novocure (NASDAQ: NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
Article
News Preview
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) from September 7 – 10, 2024 in San Diego, California. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters explor...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.